- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01889914
TReatment by Insulin Continuous Infusion in Type 2 DIAbetes (TRICIDIA2)
Treatment by Subcutaneous Continuous Infusion of Insulin by Portable Pump Versus Discontinuous Infusion of Insulin by Multi-injections in the Type 2 Diabetes: Study of the Insulinosensibility in the 2 Types of Treatments
The aim of the TRICIDIA2 study is to compare two modalities of administration of insulin.
In our future study, the investigators wish to study if the treatment by continuous infusion of insulin improves the insulinosensitivity of type 2 diabetic patients; the investigators indeed expect that the insulin delivered in a continuous way decreases the insulino-resistance of these patients compared with the intermittent delivering of insulin.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
We wish to use before and after treatment the classic tools of measure of insulinosensitivity / the euglycemic hyperinsulinemic clamp associated with a measure of the insulinosecretion thanks to a test of load in glucose IV. The coupling in the same procedure of these 2 tests is the Botnia clamp. We also wish to use the continuous measure of subcutaneous glucose during several days to estimate the reduction in the average glycemia on the fast and prandial periods as well as the decrease of the time spent in hyperglycemia during the day. This tool demonstrated its interest in type 2 diabetic population in several studies. Finally the current / spectro-IRM methods of imaging are now validated to quantify and measure exactly the importance of the steatosis, including in type 2 patients, because we know that it is probably the result of the insulino-resistance; We would also like to demonstrate that some genetic polymorphisms of proteins (polymorphisms G / T493 of the MTP, 1927 C/T of the receiver R1 of the adiponectin and 265 C/T of the gene of Apolipoprotéines A) are factors which can modulate the steatosis development in case of type 2 diabetes.
In other secondary criteria we wait for an improvement of HbA1c, quality of life of type 2 obese people with regard to the treatment by intensified Multi-injections.
Study Type
Enrollment (Anticipated)
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
-
Dijon, France, 21000
- Recruiting
- CHU
-
Contact:
- Sabine RUDONI, MD
- Email: sabine.rudoni@chu-dijon.fr
-
Principal Investigator:
- Sabine RUDONI, MD
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- age > 18 years old
- type 2 diabete patient with insuline basal/bolus treatment for at least 6 months
- Doses of insuline > 0,7 U/Kg/j
- HbA1c ≥ 7,5%
- without ADO for at least 4 weeks (sulfamides, Incrétines, glinides, acarbose) except the metformine
- BMI ≥ 28,5 kg/m²
- clinical diagnostique of diabetes for at least 10 ans
- Patient must be able to Realize an automonitoring and to manage the functioning of an insulin pump.
Exclusion Criteria:
- glitazone treatment less than 3 month before inclusion
- Patient with an untreated by the laser proliferative ischemic retinopathy
- BMI < 28,5 kg/m²
- Pacemaker (CI IRM)
- Presence of implantable material (CI IRM)
- Pregnancy, breast-feeding
- Practices of violent sports
- Professional extreme environment of cold or heat
- Serious psychiatric diseases physical and/or psychiatric Incapacitated medically significant
- Poor sanitation
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Supportive Care
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: continuous infusion of insulin by pump
in this arm called "continuous infusion of insulin with a pump" the patient receive continuous rapid insulin (APIDRA ®)with an external pump. An hepatic IRM and a botnia test will be practice before and six months after the beginning of this treatment(continuous insulin) |
Compare the efficiency of both types of therapeutic care in insulinoresistant type 2 diabetic patients: insulin multi injections (levemir et Apidra versus continuous infusion of insulin apidra by pump
Other Names:
|
Experimental: discontinuous insulin multiple injections
An arm called " intensification of the multiple daily injections ": the patient will receive an additional injection of basal insulin LEVEMIR® : five injections per day (2 injections of Levemir® and 3 injections of Apidra®) instead of four previously (1 injection of Levemir® and 3 injections of Apidra®). An hepatic IRM and a botnia test will be practice before and six months after the beginning of the treatment |
Compare the efficiency of both types of therapeutic care in insulinoresistant type 2 diabetic patients: insulin multi injections (levemir et Apidra versus continuous infusion of insulin apidra by pump
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
changes from baseline in insulinoresistance measured by biological tests of hyperinsulinemic euglycemic clamp in the two groups of treatment 6 months after the start of the treatment.
Time Frame: baseline and six months after the begining of the study
|
baseline and six months after the begining of the study
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
change from baseline in the hyperglycemia time spent during basal and prandial period with continuous glucose monitoring tool at 6 months
Time Frame: baseline and six months after the beginning of the study
|
baseline and six months after the beginning of the study
|
change from baseline in HbA1c in the two groups of treatment at three, six, nine and twelve months
Time Frame: baseline and three, six, nine, twelve months
|
baseline and three, six, nine, twelve months
|
change from baseline in quality of life measured with questionnaires at 6 months
Time Frame: baseline and 6 months
|
baseline and 6 months
|
change from baseline in weight at three, six, nine and twelve months in the two groups.
Time Frame: baseline and three, six, nine and twelve months
|
baseline and three, six, nine and twelve months
|
Collaborators and Investigators
Investigators
- Principal Investigator: Sabine RUDONI, MD, CHU de BOCAGE, DIJON, FRANCE
Study record dates
Study Major Dates
Study Start
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2011-004602-19
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Diabetes
-
University of Colorado, DenverMassachusetts General Hospital; Beta Bionics, Inc.CompletedDiabetes Mellitus, Type 1 | Type 1 Diabetes | Diabetes type1 | Type 1 Diabetes Mellitus | Autoimmune Diabetes | Diabetes Mellitus, Insulin-Dependent | Juvenile-Onset Diabetes | Diabetes, Autoimmune | Insulin-Dependent Diabetes Mellitus 1 | Diabetes Mellitus, Insulin-Dependent, 1 | Diabetes Mellitus, Brittle | Diabetes Mellitus, Juvenile-Onset and other conditionsUnited States
-
Guang NingRecruitingType 2 Diabetes Mellitus | Type1 Diabetes Mellitus | Monogenetic Diabetes | Pancreatogenic Diabetes | Drug-Induced Diabetes Mellitus | Other Forms of Diabetes MellitusChina
-
University of Trás-os-Montes and Alto DouroCompletedType 2 Diabetes Mellitus | Diabetes-Related ComplicationsPortugal
-
Northern Care Alliance NHS Foundation TrustBrighter ABCompletedDiabetes type1 | Diabetes type2United Kingdom
-
VeraLight, Inc.InLight SolutionsUnknownGestational Diabetes | Insulin Dependent Diabetes | Non Insulin Dependent DiabetesUnited States
-
Garvan Institute of Medical ResearchWeizmann Institute of ScienceActive, not recruitingType 2 Diabetes Mellitus | Pre DiabetesAustralia
-
Oregon State UniversitySanofiCompletedType I or Type II Diabetes (Excludes Gestational Diabetes)
-
Taichung Veterans General HospitalNational Health Research Institutes, TaiwanRecruitingDiabetes Complications | Type 2 Diabetes | Maturity-Onset Diabetes of the Young (MODY)Taiwan
-
University of RoehamptonRecruitingType2 Diabetes Mellitus | Pre DiabetesUnited Kingdom
-
University of ReadingCompletedDiabetes, Type 2 | Diabetes Mellitus, Noninsulin-DependentUnited Kingdom, Kuwait
Clinical Trials on 2 different procedures of administration of insulin
-
Charite University, Berlin, GermanyAbbottCompleted
-
Assistance Publique - Hôpitaux de ParisAlsius Corporation; distributed in France by; IST Cardiology (Le Fresne Camilly...CompletedHeart Arrest | HypothermiaFrance
-
TC Erciyes UniversityHacettepe UniversityCompletedType 1 Diabetes Mellitus
-
AdociaCompleted
-
Johns Hopkins UniversityTerminatedHypoglycemia | Type 1 DiabetesUnited States
-
University of New MexicoSanofiCompleted
-
Goethe UniversityNationwide Network of University Medicine (NUM) on Covid-19RecruitingSevere Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)Germany
-
Medical Research Foundation, The NetherlandsCompletedType 1 Diabetes MellitusNetherlands
-
University Hospital Schleswig-HolsteinCharite University, Berlin, Germany; German Federal Ministry of Education and... and other collaboratorsRecruiting